A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia.

Trial Profile

A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Registrational
  • Acronyms PROFICIO; TAUSSIG
  • Sponsors Amgen
  • Most Recent Events

    • 29 May 2018 Status changed from active, no longer recruiting to completed.
    • 30 Aug 2017 Results (n=14) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 21 Aug 2017 According to an Amgen media release, data feom this trial will be presented at the European Society of Cardiology (ESC) Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top